Flora Growth’s (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is hoping to begin research on its patent-pending, cannabinoid-based product. The company is requesting approval from INVIMA, the Colombian FDA, noting that recent studies indicate the potential for cannabinoids to display viral inhibition. FLGC’s research division, Flora Pharma, has filed a USPTO provisional patent application regarding the company’s cannabinoid-based formula, and the company is hoping to take the product through clinical trials under an emergency use authorization (“EUA”) from INVIMA.According to the company, the intent of the study is to identify safe and efficacious cannabinoid products for use on SARS-CoV-2 (COVID-19); FLGC plans to pursue the fastest path to market via a preventative immunomodulating product and to explore the possibility of use as a therapeutic. If the company’s request is approved, Flora’s formulation would be the first product containing cannabinoids to be approved for use against COVID-19 by the Colombian government. “We are honored to receive the advice and guidelines from INVIMA as we begin this exciting research process,” said Flora Growth president and CEO Luis Merchan in the press release. “The Flora Pharma division seeks to obtain evidence to support this product’s use against SARS-CoV-2 and bring to market an effective, cannabinoid-based product. . . . At Flora Growth, we believe in following the research, and there have been several promising studies published in just the last few months on the application of cannabinoids in certain treatments. We are excited for our Flora Pharma researchers to build upon this progress and generate new data for how cannabis could help consumers around the world, leveraging this natural, botanical alternative.”
To view the full press release, visit https://ibn.fm/JrHls
About Flora Growth Corp.
Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that delivers the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. For more information about the company, please visit www.FloraGrowth.ca.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.